Sunitinib Inhibits Tumor Growth and Synergizes with Cisplatin in Orthotopic Models of Cisplatin-Sensitive and Cisplatin-Resistant Human Testicular Germ Cell Tumors

Wilmar Castillo-Ávila,1 Josep Maria Piulats,1,2 Xavier García del Muro,2 August Vidal,3 Enric Condom,3 Oriol Casanovas,1 Josefina Mora,4 Josep Ramon Germà,2 Gabriel Capellà,1 Alberto Villanueva,1 and Francesc Viñals1,5

Abstract

Purpose: Germ cell tumors (GCT) of the testis are highly curable, but those patients who are refractory to cisplatin (CDDP)-based combination chemotherapy have a poor prognosis. Therefore, identifying new alternatives for treatment remains a priority. Several studies support an important role for angiogenesis in GCTs, suggesting that antiangiogenic treatment might be a good alternative. Sunitinib is an oral multitarget tyrosine kinase receptor inhibitor with antiangiogenic and antitumor activities. In the present study, we evaluated the effect of sunitinib, CDDP, or the combination of both drugs using an orthotopic model of human testicular GCT.

Experimental Design: Mice were implanted with four different testicular tumors: a yolk sac, two choriocarcinomas, and a CDDP-resistant choriocarcinoma variant induced in mice by continuous exposure to CDDP. Mice were treated with vehicle, CDDP, sunitinib, or the combination of both drugs and their effects on tumors were analyzed.

Results: We observed a significant inhibition in tumor growth accompanied by longer survival after sunitinib treatment. Combination therapy with CDDP significantly enhanced these effects. Sunitinib induced apoptosis, reduced tumor cell proliferation and tumor vasculature, and inhibited vascular endothelial growth factor receptor 1, 2, and 3 and platelet-derived growth factor receptor α phosphorylation without affecting phosphorylation of other tyrosine kinase receptors. More importantly, tumor growth inhibition induced by sunitinib was also observed in the induced CDDP-resistant choriocarcinoma model.

Conclusions: Taken together, these results suggest that sunitinib might be a new alternative for treatment of CDDP-refractory patients.

Germ cell tumors (GCT) of the testis are the most common solid tumors in men ages 15 to 35 years and represent 95% of tumors arising in the testes (1). Testicular GCTs can be classified as seminoma or nonseminoma according to their histologic characteristics (1). Each group represents ~50% of GCTs. Nonseminoma tumors include embryonal cell carcinoma, yolk sac tumor, choriocarcinoma, and teratoma (1). Most nonseminoma tumors are composed of two or more of these cell types; seminoma may also be a component (1).

GCTs are highly curable even in patients with metastatic disease. Approximately 70% to 80% of patients with metastatic germ cell cancer can be cured after cisplatin (cis-dichlorodiammine platinum or CDDP)-based combination chemotherapy, such as bleomycin, etoposide, and CDDP or etoposide, ifosfamide, and CDDP (2); however, resistance to CDDP treatment may arise. Indeed, two different types of resistance are observed: CDDP-refractory disease, which consists in disease stabilization during treatment followed by disease progression within 4 weeks after CDDP-based chemotherapy, and absolute CDDP-refractory disease in which there is disease progression even during treatment (3). Patients refractory to CDDP-based
Translational Relevance

Identifying new alternatives for the treatment of patients with testicular germ cell tumors (GCT) refractory to cisplatin (CDDP) chemotherapy remains a priority. In the present study, we evaluated the effect of sunitinib, an oral multitarget tyrosine kinase receptor inhibitor, in a preclinical model of testicular GCTs. Our results indicate that sunitinib has antitumor activity and that combined therapy with CDDP enhances the effect induced by either agent alone. Remarkably, sunitinib was equally effective in a CDDP-resistant model of testicular GCT. Thus, our results suggest that sunitinib might constitute a new alternative for the treatment of CDDP-refractory patients. Moreover, in clinical trials with drugs such as sunitinib, it would be interesting to continue the CDDP treatment even after development of drug resistance has taken place.

Combination chemotherapy have a poor prognosis. The identification of new treatment alternatives for patients with refractory disease remains a priority and novel molecular targets are being explored.

Antiangiogenic therapy has the potential to be an effective strategy for human cancer treatment. Angiogenesis, or the formation of new blood vessels from preexisting vasculature, is a complex multistep process that includes endothelial cell proliferation, vessel sprouting, vascular permeability, and the remodeling and maturation of emerging vessels. Angiogenesis is essential to support the growth and metastatic dissemination of most solid tumors (4, 5). A balance between proangiogenic and antiangiogenic factors controls this process. Multiple growth factors, including vascular endothelial growth factors (VEGF), fibroblast growth factors, and platelet-derived growth factors (PDGF), exert an important proangiogenic effect through binding of specific cell surface receptor tyrosine kinases (RTK). In addition to ligand activation, somatic mutations also can activate RTKs. Enhanced activity of many RTKs has been implicated in tumor growth, progression, metastasis, and angiogenesis (7).

Sunitinib is an oral multitarget RTK inhibitor with antiangiogenic and antitumor activities (8–10). Sunitinib inhibits RTKs expressed by tumor cells and involved in tumor proliferation and survival, including stem cell factor receptor (c-Kit), Fms-like tyrosine kinase 3, colony-stimulating factor type I receptor, and the glial cell line-derived neurotrophic factor receptor (8, 9). Moreover, sunitinib inhibits RTKs expressed on endothelial and mural cells, such as PDGF receptor (PDGFR; α and β) and VEGF receptor (VEGFR; types 1 and 2), which are involved in angiogenesis (8, 10). The antitumor activity of sunitinib has been shown in preclinical and clinical studies (10–15). Tumor regression has been shown in different xenograft models of colon cancer, breast cancer, non-small-cell lung cancer, melanoma, glioblastoma, renal carcinoma, and epidermal cancer (10–12). Clinically, sunitinib antitumor activity has been shown in phase I, II, and III trials in patients with renal cancer, gastrointestinal stromal tumors, breast cancer, neuroendocrine tumors, colorectal cancer, sarcoma, thyroid cancer, melanoma, and non-small cell lung cancer (11–15). In addition, sunitinib received U.S. Food and Drug Administration approval in January 2006 and European Union approval in January 2007 for treatment of advanced renal cell carcinoma and patients with gastrointestinal stromal tumors who are refractory or intolerant to imatinib (16, 17).

Several reports have shown that some of the RTKs inhibited by sunitinib and their specific ligands are implicated in the development of human testicular GCTs, such as c-Kit, PDGFRs, or VEGFRs (18–20). In the present study, we evaluated the effect of sunitinib on a newly developed model of human testicular GCTs orthotopically grown in nude mice. We used four different tumor types including yolk sac and choriocarcinoma. Because platinum-based drugs are the standard treatment for GCTs, we evaluated the antitumor and antiangiogenic activity of sunitinib alone or in combination with CDDP. Our results indicate that sunitinib clearly inhibited tumor growth, prolonged mice survival, and reduced tumor vascularization. More interestingly, sunitinib was equally effective in a CDDP-resistant model of testicular GCT, suggesting that this drug might be a new alternative for the treatment of CDDP-refractory patients in the above different tumor types.

Materials and Methods

Chemical compounds. Sunitinib was kindly provided by Pfizer and was dissolved in carboxymethylcellulose solution (carboxymethylcellulose 0.5%, NaCl 1.8%, Tween 80 0.4%, and benzyl alcohol 0.9% in distilled water) and adjusted to pH 6.0. Drug aliquots were prepared once weekly and kept in the dark at 4°C. CDDP was diluted in sterile serum before intraperitoneal injection. All other reagents were from Sigma unless stated otherwise.

Orthotopic implantation of testicular tumors. Male nu/nu Swiss mice were purchased from Charles River. Mice were housed and maintained in laminar flow cabinets under specific pathogen-free conditions. All the animal studies were approved by the local committee for animal care.

Fresh surgical specimens of GCTs of the testis were obtained after surgical resection from the Hospital Universitari de Bellvitge (L’Hospitalet de Llobregat) and Fundació Puigvert and placed in DMEM (Bio-whitaker) supplemented with 10% FCS, 50 units/ml penicillin, and 50 μg/ml streptomycin sulfate. Testicular human GCTs were minced and two pieces of each tumor were orthotopically implanted. Briefly, 5-week-old male weighing 18 to 22 g were anesthetized by isoflurane inhalation. A small midline incision was made and the testes were exteriorized. A piece of tumor was then implanted on each testis using prolene 7-0 surgical sutures. The testes were returned to the abdominal cavity and the incision was closed with wound clips. Different tumors were perfused in mice by consecutive passages (at least six) according to the growth rate of each tumor type: when an intra-abdominal mass was palpated tests and tumors were exteriorized and a piece of tumor (2.5 mm³) was then implanted on tests of a new animal as described before for the primary tumor. Only nonseminoma tumors (mainly choriocarcinomas, embryonal carcinoma, yolk sac, or mixtures) were perfused in mice; all pure seminomas present as primary tumors failed to grow as xenografts.

For our studies with sunitinib, we use four models of pure nonseminoma GCTs of the testis: a yolk sac (TGT1), two choriocarcinomas (TGT17 and TGT38), and the CDDP-resistant variant of one of the choriocarcinomas (TGT38R), which was developed by continuous exposure of mice to CDDP and shows acquired resistance to this drug. Quantification of circulating tumor markers. Serum levels of α-fetoprotein (AFP; for yolk sac tumors) and the β-subunit of human chorionic gonadotropin (βHCG; for choriocarcinomas) are used as surrogate


Quantification of circulating tumor markers. Serum levels of α-fetoprotein (AFP; for yolk sac tumors) and the β-subunit of human chorionic gonadotropin (βHCG; for choriocarcinomas) are used as surrogate
markers of tumor burden (2, 21, 22). They were measured in nude mice serum using commercially available two-site enzyme chemilumino-
metric assays automated on the Immulite-2000 analyzer. AFP assay uses 
beads coated with monoclonal murine anti-AFP and alkaline phosphatase 
conjugated to polyclonal rabbit anti-AFP (23). βHCG assay uses 
beads coated with monoclonal murine anti-βHCG and alkaline phosphatase 
conjugated to polyclonal ovine anti-βHCG (24). Reactions 
were linear up to 300 KIU/L for AFP and up to 5,000 units/L for βHCG. 
Higher concentrations were diluted with the corresponding provided 
diluents. Assay sensitivity was 0.2 KIU/L and 0.4 units/L for AFP and 
βHCG, respectively. Reference values of 59 KIU/L for AFP and ≤5 
units/L for βHCG were established based on healthy controls.

**Treatment schedule.** Approximately 10 days after tumor implantation in the case of TGT17, TGT38, and TGT38R choriocarcinomas and 30 days after tumor implantation in the case of TGT1 yolk sac tumor, a palpable intra-abdominal mass was detected. Presence of tumor was 
persistently confirmed by detection high serum levels of the surrogate 
marker human chorionic gonadotropin (hCG) for yolk sac tumors) and 
choriocarcinomas as described before. In this moment, mice were randomized 
into four treatment groups (n = 10 mice per group in TGT17 chiori-
carcinoma, n = 7 mice per group in TGT38 and TGT38R choriocarcinomas, and 
n = 5 mice per group in TGT1): (a) daily oral administration of 
sunitinib vehicle solution (carboxymethylcellulose suspension) 
for 15 days and intraperitoneal administration of three doses of physio-
logic serum at 5-day interval (control group), (b) intraperitoneal 
administration of three doses of 2 mg/kg CDDP at 5-day intervals (CDDP 
group), (c) daily oral administration of 40 mg/kg sunitinib for 15 days 
(sunitinib group), and (d) intraperitoneal administration of three doses 
of 2 mg/kg CDDP at 5-day intervals and daily oral administration of 
40 mg/kg sunitinib for 15 days (CDDP and sunitinib group). The chosen 
doses of 40 mg/kg sunitinib and 2 mg/kg CDDP were found to be the 
most effective in mice in previous studies (10).

Studies were finished when tumors in vehicle-treated animals were 
judged to adversely affect their well-being (20-25 days after tumor 
implantation for mice bearing choriocarcinoma tumors and 65-70 days 
for mice bearing yolk sac tumors). Mice were sacrificed by cervical dis-
location and the effect of the different treatments on tumor response 
was evaluated by tumor volume: volume = (length) (width² / 2).

For determination of survival time and establishment of Kaplan-
Meier survival curves, mice bearing TGT17 choriocarcinoma were 
treated with vehicle, 40 mg/kg sunitinib for 15 days, three doses of 2 mg/kg 
CDDP at 5-day intervals, and the combination of both drugs (5 mice per group). Animals were sacrificed when tumors were judged to affect 
their well-being.

**Histologic studies.** Part of the tumor from control, CDDP-treated, 
sunitinib-treated, or combination-treated mice was formalin-fixed and 
paraffin-embedded, whereas another part was embedded in OCT com-
 pound and stored at -80°C. Paraffin-embedded tissues were used to 
visualize general tissue morphology by H&E staining and to detect 
c-KIT expression by immunohistochemical staining using a 1:50 dilu-
tion of rabbit anti-c-KIT antibody (DAKO). The immunostained 
sections were counterstained using hematoxylin.

OCT-frozen sections were used for immunofluorescence staining. 
Double immunofluorescence staining was done to detect CD31/Desmin, 
CD31/Ki-67, CD31/activated caspase-3, and PDGF-Rα/Desmin expres-
  sion. Sections were incubated overnight at 4°C with a 1:50 dilution of 
  rabbit monoclonal antibody for CD31 (BD Pharmingen) and either 
a 1:500 dilution of rabbit antibody for Desmin (NeoMarkers), a 1:100 
dilution of rabbit antibody for Ki-67 (NeoMarkers), or a 1:500 dilution of 
rabbit antibody for activated caspase-3 (Cell Signaling). For double 
immunofluorescence staining of PDGF-Rα/Desmin, sections were incu-
bated overnight at 4°C with a 1:100 dilution of rat antibody for PDGF-Rα 
(eBioscience) and a 1:500 dilution of rabbit antibody for PDGF-Rα. 
Sections were washed twice with PBS and incubated with a 1:300 dilution 
of Alexa Fluor 488-conjugated goat anti-rabbit plus a 1:200 dilution of 
Alexa Fluor 546-conjugated goat anti-rat (Molecular Probes) at room 
temperature for 1 h in the dark. The slides were then washed twice in 
PBS and incubated with a 1:1,000 dilution of TO-PRO-3 (Molecular 
Probes) for 10 min in the dark. Finally, the slides were washed twice in 
PBS and coverslips were mounted using Gel Mount aqueous mounting 
medium (Sigma).

To identify apoptotic cells, terminal deoxynucleotidyl transferase-
mediated biotin-dUTP nick end labeling (TUNEL) staining (Promega) 
was used following the manufacturer’s protocol. Briefly, after incuba-
tion of samples with equilibration buffer for 5 to 10 min at room 
temperature, sections were incubated with TdT reaction mix at 37°C for 
1 h inside a humidified chamber. Then, samples were washed with 
2× SSC and PBS and incubated with a 1:50 dilution of rat anti-mouse 
monoclonal antibody for CD31 (BD Pharmingen). Sections were 
 washed twice with PBS and incubated with a 1:500 dilution of strepta-
vidin 488 FITC and a 1:200 dilution of Alexa Fluor 546-conjugated goat 
anti-rat (Molecular Probes) for 1 h at room temperature. Finally, sam-
  ples were incubated with a 1:1,000 dilution of TO-PRO-3 for 10 min in 
the dark.

Images of sections were obtained on a Leica TCS SL spectral confocal 
microscope. To quantify CD31, Ki-67, and TUNEL staining, five hotspot 
fields in viable tissue zones at ×400 magnification were captured for each 
tumor. Quantification of staining areas was done using ImageJ 
software.

**RTK array analysis.** To determine which tyrosine kinase receptors 
were targeted by sunitinib, a human Phospho-RTK Array (R&D Systems) 
was used to detect the tyrosine phosphorylation levels of 42 differ-
ent RTKs. Mice bearing TGT38 choriocarcinoma were treated with 
sunitinib (40 mg/kg) or vehicle alone for 15 days. Mice were sacrificed 
4 h after the last dose. Tumor samples obtained from 4 control and 
4 sunitinib-treated mice were mechanically disrupted using lysis buffer 
[1% NP-40, 20 mmol/L Tris-HCl (pH 8.0), 137 mmol/L NaCl, 
10% glycerol, 2 mmol/L EDTA, 1 mmol/L sodium orthovanadate, 10 
g/μL apomycin, 10 μg/mL leupeptin] and a glass homogenizer on 
ice. Protein concentration was determined using a BCA assay kit 
(Pierce). RTK array analysis was done according to the manufacturer's 
protocol. Array membranes were blocked and incubated with 500 μg 
mouse lysate overnight at 4°C on a rocking platform shaker. Then, 
the arrays were washed, incubated with anti-phosphotyrosine horserad-
ish peroxidase for 2 h at room temperature, washed again, and devel-
oped with ECL. Western blotting detection reagent (Amersham 
Pharmacia Biotech). Average pixel density of duplicate spots was deter-
mined using the Quantity One software, and values were normalized 
among control duplicate phosphotyrosine-positive control spots. Results 
were expressed as a ratio of sunitinib-treated to untreated samples.

**Quantitative real-time PCR.** Real-time PCR of cDNA obtained from 
TGT17, TGT38, and TGT1 tumors was done with SYBR Green (Roche 
Molecular Biochemicals) and specific primers for human PDGF-Rα (5′-
AGTTCCTTCATCCATCTGGACT and 5′-GGGTATGGGTTTGTCACTGAG), 
mouse PDGF-Rα (5′-GAGCGCTCTTCATAA and 5′-GGACACTCGACCTGGT), 
human PDGF-Rβ (5′-CATCACCCTGTGTTGAG and 5′-AATTTGATCCTGGACCCCTCT), 
mouse PDGF-Rβ (5′-CACTGAGCAGTACCTCCTTTGAG and 5′-GATATGCAGGAGTTTCAACGC), 
human PDGF-Rβ (5′-TGTAAGCTTCTGTCGCTCTC), and specific primers for 
human PDGF-Rβ (5′-AGCGAGGCCGCTCTTTGAC and 5′-GAGGCCGCAAGGAGTTTCAACGC) 
designed using the Primer3 software. Real-time PCR was run on a LightCycler instrument (Roche Molecular Biochemicals). Forty 
cycles of amplification with denaturation at 95°C for 10 s followed by 
amplification at 65°C for 20 s and extension at 72°C for 15 s were done 
after an initial incubation at 95°C for 10 min. The ΔCt values were 
calculated after subtracting the mean Ct values of β-actin gene from the 
receptor gene mean Ct values.

**Cell culture.** Human 141H is a yolk sac carcinoma cell line derived from a testicular teratomacarcinoma and obtained from European Col-
lection of Cell Cultures. Cells were cultured in DMEM high glucose
Biowhittaker) supplemented with 10% FCS, 50 units/mL penicillin, 50 μg/mL streptomycin sulfate, and 2 mmol/L glutamine.

**Western blotting.** 1411H cells were grown to 80% of confluence in a 6-well plate and incubated with DMEM in the absence or presence of increasing concentrations of sunitinib or CDDP. After 24 h of incubation, cells were washed twice in cold PBS and lysed for 15 min at 4°C in radioimmunoprecipitation by RIPA lysis buffer (0.1% SDS, 1% NP-40, 0.5% sodium deoxycholate, 50 mmol/L NaF, 5 mmol/L EDTA, 40 mmol/L β-glycerophosphate, 200 μmol/L sodium orthovanadate, 100 μmol/L phenylmethylsulfonyl fluoride, 1 μmol/L pepstatin A, 1 μg/mL leupeptin, 4 μg/mL aprotinin). Insoluble material was removed by centrifugation at 12,000 × g for 5 min at 4°C. Proteins from cell lysates were separated on acrylamide/bisacrylamide (29:1) SDS gels and electrophoretically transferred to Immobilon-P membranes (Millipore) in 25 mmol/L Tris-HCl, 0.19 mol/L glycine, and 15% methanol. Membranes were blocked in TBS [150 mmol/L NaCl, 50 mmol/L Tris

**Fig. 1.** Angiogenic pattern of TGT17, TGT38, and TGT1 testicular xenograft models. A, dual staining for the endothelial marker CD31 and the pericyte marker desmin. Bar, 80 μm. B, determination of VEGFR2, PDGFRα, and PDGFRβ expression in TGT17 and TGT38 choriocarcinomas and TGT1 yolk sac tumors. mRNA level of human and mouse VEGFR2 and PDGFRα and PDGFRβ were analyzed by quantitative real-time PCR. Mean ± SD of mRNA expression (four tumors per group) relative to human or mouse testis controls. C, determination of tumoral and stromal expression of PDGFRα by immunofluorescence in TGT38 choriocarcinoma. Bar, 80 μm.
**Fig. 2.** Effect of sunitinib and CDDP on tumor growth in testicular xenograft models. TGT1 yolk sac and TGT17 and TGT38 choriocarcinomas were implanted orthotopically in the testis of male nude mice. Animals were treated with vehicle (untreated), three doses of 2 mg/kg CDDP, 40 mg/kg sunitinib for 15 d, or their combination (n = 5 mice per group in TGT1 and n = 7 mice per group in TGT17 and TGT38). A, sunitinib and CDDP as single agents reduced tumor volume and their combination improved this effect. *, P < 0.05. B, circulating βHCG and AFP levels detected in serum of mice bearing TGT1 yolk sac and TGT38 choriocarcinoma at different days post-tumor implantation. Bars, SD. C, Kaplan-Meier survival curves of sunitinib and CDDP-treated mice. Mice bearing TGT17 choriocarcinoma (n = 5 mice per group) were treated with vehicle, three doses of 2 mg/kg CDDP, 40 mg/kg sunitinib for 15 d, or the combination of both drugs. Increase in survival induced by sunitinib and CDDP treatment was enhanced by their use in combination. *, P < 0.05.

(pH 7.4]) containing 5% nonfat dry milk for 1 h. The blots were incubated with polyclonal rabbit anti-poly(ADP-ribose) polymerase antibody (Cell Signaling), polyclonal rabbit anti-active caspase-3 antibody (Cell Signaling), polyclonal rabbit anti-PDGFRα antibody (Santa Cruz Biotechnology), or monoclonal anti-tubulin antibody (Sigma) in blocking solution overnight at 4°C. After washing in TBS-0.1% Triton X-100, blots were incubated with anti-rabbit immunoglobulin (Amersham Pharmacia Biotech) or anti-mouse immunoglobulin (Amersham Pharmacia Biotech) horseradish peroxidase-linked antibodies in blocking solution for 1 h and developed with an enhanced chemiluminescence system (Amersham Pharmacia Biotech).

3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyloxazole bromide assay. Cell proliferation was determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyloxazole bromide (MTT) assay. 1411H cells were plated in triplicate wells (25,000 per well) and allowed to grow for 24 h. Cells were incubated in the absence or presence of increasing concentrations of sunitinib or CDDP for additional 24 h. After this time, 10 μmol/L MTT (Sigma) was added to each well for an additional 4 h. The blue MTT formazan precipitate was dissolved in 200 μL DMSO. The absorbance at 570 nm was measured on a multiwell plate reader. Cell viability was expressed as a percentage of the control and data are shown as mean ± SD of three independent experiments.

**Statistical analyses.** Statistical significance of differences in in vitro cell proliferation and in tumor growth, and TUNEL, CD31, and Ki-67 expression between control and treated tumors was determined using the Mann-Whitney U test. The log-rank test was done to compare survival curves from the different treatment groups. In all experiments, differences were considered statistically significant when P < 0.05.
Results

Sunitinib induces inhibition of tumor growth in testicular orthotopic models and synergizes with CDDP. Our aim was to evaluate antiangiogenic therapy as an alternative to CDDP in testicular GCTs. For this, we used new orthotopic models of human testicular GCT recently developed in our laboratory; these models, all generated from nonseminoma human GCTs, have been shown to accurately reproduce the histologic and genetic characteristics of these testicular GCTs as well as their response to CDDP. We used three different orthotopic GCTs of the testis chosen because of their belonging solely to a specific histologic
type: a yolk sac (TGT1) and two choriocarcinomas (TGT17 and TGT38). First, we analyzed the angiogenic pattern and the expression of several proangiogenic RTKs in these tumors. Orthotopic GCTs were highly vascularized, presenting high vessel density positive for CD31 (an endothelial marker) but also for desmin (a pericyte marker; Fig. 1A). Concerning RTKs, we analyzed the mRNA expression of VEGFR2, PDGFRα, and PDGFRβ using quantitative real-time PCR. We designed primers that specifically recognized human or mouse mRNA to discriminate between receptors expressed by human tumor cells or mouse stromal cells in our xenograft model. Thus, VEGFR2 was only expressed in the mouse endothelial compound and absent in human tumoral cells (Fig. 1B). PDGFRβ presented a similar expression profile as that of VEGFR2, being expressed only by the stromal compound of tumors. In contrast, PDGFRα was not only expressed by the mouse stromal compound but also by human tumoral cells. To confirm this, PDGFRα protein expression was analyzed by immunofluorescence. PDGFRα expression was detected in stromal desmin-positive mural cells but also in tumoral cells (Fig. 1C; Supplementary Fig. S1). We did not detect the expression of other RTKs such as c-Kit or Fms-like tyrosine kinase 3 expression in our GCT model (Supplementary Fig. S1; data not shown). Altogether, these data suggested that a multitarget RTK inhibitor such as sunitinib, which also displays antiangiogenic activity, could be an optimal candidate for the treatment of these tumors.

Next, we examined the effect of sunitinib and CDDP on the growth of these tumors. Mice were treated with vehicle (untreated), CDDP, sunitinib, or the combination of both drugs as described in Materials and Methods. All animals were sacrificed once tumors of the control group adversely affected their well-being; the effect of the different treatments was determined by measuring tumor volume (Fig. 2A). As expected, CDDP treatment reduced tumor volume in all cases. Treatment with sunitinib as a single agent also resulted in a reduction of tumor volume compared with the control group. Combination therapy with sunitinib and CDDP enhanced the antitumor activity of these drugs, inducing a significantly greater decrease in tumor volume than that observed in any of

Fig. 4. Sunitinib reduces cell proliferation and vessel density. A, dual staining for Ki-67 proliferation marker and CD31 endothelial marker was done in viable zones of tumors from mice bearing TGT38 choriocarcinoma treated as in Fig. 2. Bar, 80 μm. CD31 (B) and Ki-67 (C) expression was quantified using ImageJ software. Mean ± SD of five sections of each tumor (seven tumors per treatment group), expressed as the percentage of area with positive CD31 or Ki-67 staining relative to untreated group. *, P < 0.05.
the other arms of the study. In the case of TGT17 choriocarcinoma, tumors treated with the combination of sunitinib and CDDP completely regressed.

We used circulating serum levels of βHCG and AFP as surrogate markers of tumor burden (for choriocarcinoma and yolk sac tumors, respectively; Fig. 2B). CDDP and sunitinib, alone or in combination, reduced βHCG and AFP levels with respect to the control group, suggesting that these treatments inhibit tumor burden.

Combination of sunitinib and CDDP increases mice survival.

To determine whether the administration of CDDP, sunitinib, or their combination was able to prolong survival in animals with testicular GCTs, athymic mice bearing TGT17 choriocarcinoma were randomized into four treatment groups as described above. Mice were maintained until death for Kaplan-Meier analysis (Fig. 2C).

Median survival time of control group was 13 days. CDDP and sunitinib treatment enhanced mouse survival compared with the control group (median survival times were 33 and 36 days, respectively). There were no significant differences in median survival time between both treatments. However, the coadministration of the two drugs increased the median survival compared with the controls but also compared with single-agent treatment with CDDP or sunitinib (median survival time of combined therapy was 47 days).

Sunitinib promotes apoptosis and reduces microvascular density and cell proliferation. To understand the mechanisms that contribute to tumor growth inhibition induced by sunitinib, tumor sections from control or treated mice bearing TGT38 choriocarcinoma were evaluated by histologic and immunohistochemical analysis. H&E staining showed significant tumor necrosis in tumors treated with CDDP alone or combined with sunitinib. Percentage of necrotic tissue was ~80% for tumors from CDDP-treated mice and 90% for tumors from CDDP and sunitinib-treated mice, whereas necrosis represented only 20% of tumor in samples from sunitinib-treated mice (Fig. 3A).

Sections from tumors were further subjected to TUNEL staining to determine whether apoptosis could be involved in the reduction in tumor volume induced by the different treatments (Fig. 3B). Administration of CDDP alone or in combination with sunitinib had little effect on apoptosis in choriocarcinoma tumors. However, sunitinib induced a 2.5-fold increase in apoptotic cells compared with untreated tumors (Fig. 3C). These results were confirmed by immunodetection of activated caspase-3, an early and specific apoptotic marker. We also observed an increase in activated caspase-3

![Graph A](image1.png)

**Fig. 5.** A, sunitinib inhibits RTKs involved in angiogenesis and tumor growth. Mice bearing TGT38 choriocarcinoma were treated with vehicle or 40 mg/kg sunitinib for 15 d and sacrificed 4 h after the last dose. Tumors were resected and phosphorylation levels of different RTKs were analyzed using a human phospho-RTK array kit. Data are ratio between the phosphorylation level of RTKs detected in sunitinib treated and untreated mice. B, *in vitro* sunitinib effect on 1411H cell apoptosis. Cells were incubated in the absence or presence of the indicated concentrations of sunitinib or CDDP for 24 h. Cells were lysed and PDGFRα, poly(ADP-ribose) polymerase (** cleared form), active caspase-3, and tubulin (as a loading control) were immunodetected by immunoblotting. C, MTT assay was done to analyze the effect of sunitinib and CDDP on tumor cell proliferation. 1411H cells were treated as in B. Percentage of cell proliferation relative untreated control cells. *, P < 0.05. Average of three different experiments.
staining in sunitinib-treated tumors (Supplementary Fig. S2). In yolk sac tumors, sunitinib and also CDDP increased apoptotic cells (Supplementary Fig. S3). We then studied the possible apoptotic effect of each treatment on endothelial cells. In this case, we observed a significant increase of apoptosis in this cell type both in sunitinib-treated tumors and also in tumors treated with the combined therapy (Fig. 3D; Supplementary Fig. S3).

We also analyzed the effect induced by the three treatments on tumoral cell proliferation using Ki-67 staining. In all cases, we observed lower Ki-67 levels in tumors from treated mice than in those from tumors controls, indicating a decrease in cell proliferation (Fig. 4A and B; Supplementary Fig. S3).

To better understand the effect of sunitinib, we analyzed the effect of the different treatments on tumor vascular endothelium. CD31 endothelial marker staining was done (Fig. 4A) and quantified (Fig. 4C). No differences in staining were observed between tumors from control or CDDP-treated mice. However, sunitinib treatment and the combination of sunitinib and CDDP resulted in a decrease of ~50% in CD31 expression compared with control mice, indicating a reduction in tumor vasculature. These results are consistent with the apoptotic effect induced by sunitinib alone or in combination with CDDP on endothelial cells.

Sunitinib inhibits RTKs involved in angiogenesis and tumor growth. Next, to determine which receptors were being targeted by sunitinib in our model, we used a human phospho-RTK array kit that detects the phosphorylation level of 42 different RTKs, including PDGFR and VEGFR. Mice bearing TGT38 choriocarcinoma treated with vehicle or sunitinib for 2 weeks were treated with vehicle or sunitinib for an additional 4 h. Animals were then sacrificed, the tumors were extracted, and phosphorylation levels of different RTKs were analyzed (Fig. 5A). It was shown that sunitinib inhibited phosphorylation of PDGFRα and VEGFR1 to VEGFR3. However, inhibition of PDGFRβ (which has also been described as a sunitinib target) or non- sunitinib target receptors (such as epidermal growth factor receptors) was not observed. These results suggested that sunitinib could also be exerting a direct effect on tumor cells.

To confirm or discard this hypothesis, we performed in vitro experiments using a tumoral cell line isolated from a yolk sac testicular carcinoma, human 1411H cells. These cells express PDGFRα as we confirmed by Western blot (Fig. 5B). To study a possible effect of sunitinib-inducing apoptosis on these cells, we examined by Western blot the activation of a typical apoptotic signaling pathway [caspase-3 activation and poly(ADP-ribose) polymerase cleavage]. Sunitinib, as CDDP, increased apoptosis in these cells activating this proapoptotic pathway.

Fig. 6. Sunitinib inhibited tumor growth in a CDDP-resistant model of testicular GCT. Mice bearing the CDDP-resistant variant of TGT38 choriocarcinoma (TGT38R) were treated with vehicle, three doses of 2 mg/kg CDDP, 40 mg/kg sunitinib for 15 d, or their combination. Histologic characterization (A) and tumor volume (B) were analyzed. A, H&E staining showed increased necrosis only in CDDP + sunitinib-treated tumors, whereas percentage of necrotic tissue in CDDP or sunitinib-treated tumors was very low. Bar, 200 μm. B, combined therapy did not improve the effect on tumor volume induced by either compound. *, P < 0.05.
Effect of sunitinib on a CDDP-resistant model of testicular GCT. As mentioned before, a small proportion of patients diagnosed with GCTs are refractory to standard treatment with CDDP. Because our previous results indicated that sunitinib inhibited tumoral growth by mechanisms other than those of CDDP, we analyzed the effect of sunitinib treatment on a CDDP-resistant model. We used mice bearing TGT38R choriocarcinoma, a variant of TGT38 choriocarcinoma induced by continuous exposure of mice to CDDP, which displays acquired resistance to this drug (Fig. 6B).6 Mice treated with vehicle, CDDP, sunitinib, or their combination were sacrificed when moribund and H&E staining and tumor volume determination were done. H&E staining showed significant tumor necrosis only in tumors treated with CDDP in combination with sunitinib (Fig. 6A). As expected, there were no significant differences in tumor volume between control and CDDP-treated mice. However, sunitinib treatment alone induced a significant reduction in tumor volume; the effect induced by the combination with CDDP was of similar magnitude, suggesting that CDDP does not further improve the effect of sunitinib (Fig. 6B). As expected, sunitinib induced apoptosis in both tumoral and endothelial cells and blocked tumoral cell proliferation (Supplementary Fig. S4).

Discussion

Angiogenesis has recently arose as an interesting therapeutic target to explore in testicular GCTs. Serum levels of key tumor-derived proangiogenic factors such as VEGF, basic fibroblast growth factor, and PDGF are increased in patients with testicular GCTs (25, 26). Increased expression of VEGF has also been associated with metastatic disease in GCTs (27). Moreover, many RTKs known to play an important role in angiogenesis, such as VEGFR2 and PDGFRs, have also been implicated in the pathogenesis of testicular GCTs (28). Our data using newly developed preclinical orthotopic models of nonseminomatous human testicular GCTs confirm that these tumors are highly vascularized and express many RTKs implicated in angiogenesis. Therefore, we have shown that these new orthotopic GCT models are a useful tool to evaluate antiangiogenic compounds.

Sunitinib is a small multitarget RTK inhibitor with antitumor activity exerted through both its antiproliferative and its antiangiogenic effects. The antiproliferative effect of sunitinib has been previously described in several human cancer cell lines and human xenograft models including renal, breast, lung, melanoma, glioblastoma, and epidermoid carcinoma (8–10, 12). Thus, we assayed the effect of sunitinib in our preclinical orthotopic models of nonseminomatous testicular GCTs. Our results show that sunitinib as a single agent inhibits tumor growth in different types of testicular GCTs, including choriocarcinoma and yolk sac tumors, by inducing apoptosis and inhibiting cell proliferation. Furthermore, we observed a reduction of ~50% in tumor microvessel density in sunitinib-treated tumors. These results confirm the effect observed in previous reports describing the antiangiogenic activity of sunitinib. Previous in vitro studies show that sunitinib inhibits proliferation and migration of human umbilical vein endothelial cells and reduces capillary-like tubule formation (29). Antiangiogenic activity has also been shown in vivo: sunitinib has been shown to reduce microvessel density in an orthotopic model of glioblastoma and also to prevent neovascularization in a tumor vascular window model (9, 12, 21).

Multitarget agents are directed against several cancer-specific molecular targets. In our model, we show that sunitinib inhibits VEGFR and PDGFRs. We believe that the antiangiogenic effect induced by sunitinib is due to inhibition of endothelial cell receptors but also to inhibition of PDGFRs expressed on mural cells that support tumor vasculature. However, our results suggest that, in addition to this antiangiogenic activity, sunitinib could also exert its antitumor effect through a direct inhibition of PDGFRs expressed on tumor cells. Several reports describe the antitumor effect induced by targeting tumor PDGFRs, as in the case of imatinib, a drug that inhibits tumor growth and leads to apoptosis by selective inhibition of PDGFR in some cancer models (30, 31). But more interestingly, previous reports have shown that the antitumor effect induced by inhibition of PDGFRs is enhanced by simultaneously inhibiting VEGFRs, suggesting the importance of the inhibition of both PDGFRs and VEGFRs for antitumor activity (31, 32). Moreover, the antitumor effect induced by the combination of two independent agents that inhibit PDGFRs and VEGFR is similar to that observed with sunitinib treatment alone (31). These results are consistent with the potent antitumor effect induced by sunitinib in our models, where we show simultaneous inhibition of VEGF and PDGF. In fact, a phase II study of testicular GCTs aiming to determine the activity of imatinib in chemorefractory patients failed to detect any significant antitumor effect (33, 34). The results described above suggest that sunitinib could be an interesting alternative for these patients due to its simultaneous inhibition of PDGFRs and VEGFRs.

Targeted therapies are often useful in combination with standard chemotherapy because their mechanisms of action and cellular targets are often different and do not overlap. Because CDDP-based chemotherapy is the standard treatment for patients with GCTs of the testis, we analyzed the effect induced by CDDP alone or in combination with sunitinib in the different orthotopic models of testicular GCTs used in this study. There were no significant differences between the effect of sunitinib and that of CDDP on tumor growth inhibition and survival. However, a synergistic effect was observed with the combination of both drugs, confirming that their effects are exerted through different mechanisms: whereas CDDP is a cytotoxic agent that induces DNA damage resulting in a very high percentage of necrosis, sunitinib induces apoptosis through inhibition of several RTKs involved in tumor growth and survival. Furthermore, sunitinib also displayed antiangiogenic activity increasing apoptosis, whereas CDDP treatment did not appear to have any effect on endothelial cell apoptosis. Our results are consistent with previous reports that show the synergistic effect of sunitinib with CDDP-based chemotherapy in a small cell lung cancer xenograft model (9) and with other chemotherapy agents such as docetaxel, 5-fluorouracil, or doxorubicin in breast cancer models (35). In all cases, the effect of combined therapy was greater than the effect induced by single agents.
GCTs are highly sensitive to chemotherapy and respond well to CDDP-based treatment. However, ~15% to 20% of patients with metastatic nonseminomas are refractory to this treatment and have a poor prognosis. New treatment alternatives for these patients are necessary. A large number of chemotherapeutic agents, such as gemcitabine, temozolomide, irinotecan, or oxaliplatin, have been evaluated in CDDP-refractory testicular GCT patients, but only partial and transient clinical activity could be shown for the majority of these agents (33, 36). Taking into account all the different mechanisms of tumor growth inhibition previously described for CDDP and sunitinib, we analyzed the effect of sunitinib on a CDDP-resistant model of testicular GCT. Our results show that sunitinib also inhibited tumor growth in this CDDP-resistant model, indicating that sunitinib can exert its antitumor effect unaffected by the CDDP-resistant phenotype. Moreover, the effect appeared to be greater than in the nonresistant model (compare sunitinib effect in Fig. 2 in TGT38 with that obtained in Fig. 6 in TGT38R). Combination of both drugs caused significant tumor necrosis in CDDP-resistant tumors, absent when these tumors were treated with CDDP or sunitinib alone (Fig. 6), confirming that the combination of both drugs presents a synergistic, enhanced effect. Put together, our results from our preclinical models suggest that it could be interesting to maintain CDDP treatment in clinical trials even after development of drug resistance has taken place.

In conclusion, our results show that sunitinib as a single agent has antitumor and antiangiogenic activity in preclinical models of testicular GCTs. In addition, the administration of sunitinib in combination with CDDP enhances the effect induced by either agent alone, showing the benefits of combined therapy using two drugs with different mechanisms of action. Finally, sunitinib also exhibits a potent effect on a CDDP-resistant model. Therefore, sunitinib arises as a promising novel therapeutic alternative for this disease even in CDDP-refractory testicular GCT patients.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Acknowledgments
We thank Benjamin Torrejón (Serveis Científico-Tècnics de la Universitat de Barcelona) and Carmen Bleda (Servei de Farmàcia, Institut Català d’Oncologia, Hospital Duran i Reynals, L’Hospital de Llobregat) for technical support and James Christensen (Pfizer) for helpful suggestions.

References
25. Osukey KL, Hallahan DE, Fu A, Ye F, Shyr Y, Geng L. The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis 2004;7:225–33.
26. McGarry EC, Weber K, Mills L, et al. Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine...
Sunitinib Inhibits Tumor Growth and Synergizes with Cisplatin in Orthotopic Models of Cisplatin-Sensitive and Cisplatin-Resistant Human Testicular Germ Cell Tumors

Wilmar Castillo-Ávila, Josep Maria Piulats, Xavier Garcia del Muro, et al.


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/15/10/3384

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2009/05/20/1078-0432.CCR-08-2170.DC1

Cited articles
This article cites 36 articles, 17 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/15/10/3384.full.html#ref-list-1

Citing articles
This article has been cited by 10 HighWire-hosted articles. Access the articles at:
/content/15/10/3384.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.